Streptococcus pneumoniae capsular polysaccharide serotype 9V (9V CPS)

The Streptococcus pneumoniae capsular polysaccharide serotype 9V (9V CPS) is a high-molecular-weight linear polymer composed of a repeating pentasaccharide unit containing D-glucuronic acid, D-galactose, 2-acetamido-2-deoxy-D-mannose (β-ManNAc), and two D-glucose residues, with partial O-acetylation (approximately 1.6-2 equivalents per repeat, including at β-ManNAc-6 position mediated by wcjE). This capsule is a dominant surface structure that functions as a key virulence factor by shielding the bacterium from host phagocytosis and opsonophagocytic clearance, contributing to invasive pneumococcal diseases such as pneumonia, meningitis, and bacteremia. Structurally, 9V CPS differs from related serotype 9A by the presence of wcjE-dependent 6-O-acetylation on β-ManNAc, which enhances immunogenicity and is preferentially targeted by human antibodies post-vaccination, conferring serotype-specific epitopes recognized by typing sera and monoclonal antibodies. The wcjE gene enables this modification, and its loss-of-function mutation leads to serotype switching to 9A, potentially evading immune responses. As a therapeutic target, 9V CPS is incorporated into pneumococcal conjugate vaccines like the 13-valent PCV, where it is conjugated to carrier proteins to elicit protective IgG antibodies that promote bacterial opsonization and clearance. This antigen's role underscores its importance in vaccine strategies against Streptococcus pneumoniae, though challenges include limited cross-reactivity and emergence of non-vaccine serotypes.

Other names

serotype 9V capsule polysaccharide9V polysaccharide (PS)American type 68 polysaccharide

Induction of opsonophagocytic antibodies targeting CPS for bacterial clearance